SPRI | Breast Disease: Management And Therapies. Volume 2 (2016 EN)

Discussion in 'Medicine' started by Kanka, Nov 16, 2016.

  1. Kanka

    Kanka Well-Known Member Loyal User

    Messages:
    16,037
    Likes Received:
    449
    Trophy Points:
    83
    [​IMG]

    Author: Adnan Aydiner (Editor), Abdullah Igci (Editor), Atilla Soran (Editor)
    Full Title: Breast Disease: Management And Therapies. Volume 2
    Publisher: Springer; 1st ed. 2016 edition (May 10, 2016)
    Year: 2016
    ISBN-13: 9783319260129 (978-3-319-26012-9), 9783319260105 (978-3-319-26010-5)
    ISBN-10: 331926012X, 3319260103
    Pages: 934
    Language: English
    Genre: Internal Medicine
    File type: PDF (True)
    Quality: 10/10
    Price: 238.16 €



    This second volume of the handbook on breast disease provides a comprehensive overview of its clinical management and current therapies. It brings readers up to speed with the latest guidelines and therapeutic regimens in breast cancer and provides and in-depth account of current and new therapeutic approaches.

    Divided in themed parts, the book examines invasive breast cancer, pre-operative systemic therapy surgical management and recurrence among others, thus providing an in-depth account of breast cancer at the clinical stage. Among the themed parts are a section dedicated to special therapeutic problems, such as breast cancer in older women, Paget’s disease and phyllodes tumors, and a section on supportive and follow-up care.

    By adopting a multidisciplinary approach to breast cancer, this book is a must- have for breast cancer practitioners. With a high number of colored illustrations and edited by highly experienced clinicians, this work enables readers to gain an interdisciplinary perspective on breast diseases. Contributions from an international team of experts present invaluable insight into clinical practice across different settings. Covering both theoretical and practical aspects of breast cancer, this is a highly informative and carefully presented book which will appeal to an international audience of medical, radiation and surgical oncologists.

    -------------
     
    Last edited by a moderator: Dec 5, 2019